Zacks: Brokerages Anticipate CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to Post -$0.04 Earnings Per Share
Analysts predict that CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will post earnings of ($0.04) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for CASI Pharmaceuticals’ earnings. CASI Pharmaceuticals posted earnings of ($0.08) per share during the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Monday, August 21st.
On average, analysts expect that CASI Pharmaceuticals will report full-year earnings of ($0.16) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.19) to ($0.16). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow CASI Pharmaceuticals.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01.
Separately, Maxim Group set a $4.00 price objective on CASI Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, May 16th.
Shares of CASI Pharmaceuticals (NASDAQ CASI) traded down 1.3220% during midday trading on Friday, hitting $1.1644. 12,866 shares of the stock traded hands. The company’s 50 day moving average price is $0.99 and its 200-day moving average price is $1.21. The stock’s market cap is $70.09 million. CASI Pharmaceuticals has a 12-month low of $0.82 and a 12-month high of $1.76.
A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Wellington Shields Capital Management LLC increased its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 37.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 728,447 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the period. Wellington Shields Capital Management LLC owned about 1.21% of CASI Pharmaceuticals worth $1,034,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.90% of the company’s stock.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.